Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHFINDER: Multimodal General Anesthesia in Cardiac Surgery
NCT04016740Phase 1Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Targeted Liposomes, Orthosteric Ligands, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of ropivacaine hydrochloride liposomal suspension injection, ketamine, remifentanil, dexmedetomidine, rocuronium and 2 more in coronary artery disease (CAD) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Incidence of Delirium. Started Aug 2019; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injectionketamineremifentanildexmedetomidinerocuronium
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04016740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016740.